ePrivacy and GPDR Cookie Consent by Cookie Consent

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity


Nov. 4, 2019


Activating ERBB2 mutations are found at low prevalence across multiple cancer types. Pre-clinical studies identify poziotinib as an active therapeutic, confirmed by early clinical data in NSCLC (ORR 42%, n=12 patients treated).